A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622

Trial Profile

A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2018

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Hypereosinophilic syndrome
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline Research & Development
  • Most Recent Events

    • 19 Feb 2018 Planned End Date changed from 6 Aug 2019 to 5 Mar 2020.
    • 19 Feb 2018 Planned primary completion date changed from 6 Aug 2019 to 5 Mar 2020.
    • 05 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top